Drug intelligence / Profile preview

CEQ501

Development stage: Discontinued
Lead developer: Marina Biotech
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CEQ501 is an experimental oral RNA interference (RNAi) therapeutic developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition characterized by the development of numerous precancerous polyps in the colon. Developed by Cequent Pharmaceuticals, the drug utilizes a proprietary TransKingdom RNAi (tkRNAi) platform. This technology employs engineered, non-pathogenic *Escherichia coli* as a delivery vehicle to transport short hairpin RNA (shRNA) directly into intestinal epithelial cells. The shRNA is designed to silence the *CTNNB1* gene, which encodes beta-catenin, a protein whose overexpression drives polyp formation in FAP. Following the acquisition of Cequent by MDRNA (later Marina Biotech) in 2010, CEQ501 served as the lead candidate before being succeeded by CEQ508, a refined version of the same therapeutic approach.

Targets

CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on CEQ501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEQ501.

Explore the full profile